Published: 2017-02-20

Relationship of expression of HER 2 protein according to histological type tumors by lauren in gastric cancer

Amir Spahić, Branislava Jakovljević


Background: Gastric cancer, by the definition of World Health Organization (WHO), is a malignant epithelial tumor of mucosa of the stomach with glandular differentiation. Objective of this Scientific paper was to maintain the relation of expression of HER2 protein and hystological type of cancer according to Lauren in gastric cancer.

Methods: In this research, archival samples of tissues of gastric cancer are used from 60 patients that have been obtained after subttotal or total Gastrectomy with a regional lymphadenectomy of lymph nodes. The most representative tissue samples of gastric cancer tissues are selected by the standard hematoxylin-eosin staining method which are cut again by using a microtome and treated by immunohistochemistrical technique with antibody on the HER2 according to the protocol of the producer and then evaluated by light-microscopic and again evaluated by a modified system of scoring the HER2 positivity of surgical resections. In the data processing, descriptive statistics and nonparametric test of significance respectively. Chi square test and one sample T-test, and also correlation tests respectively Pearson test of correlation.

Results: Statistical analysis of expression of HER2 protein according to hystological type of gastric cancer done by chi-square test, does not show significant relation between these two variables (x2=4,900). Analysis by using one sample T-test does not show statistical significance (t=1.1880), and analysis by using Pearson test of correlation shows negative correlation that is not statistically significant (r= -0.029) between these two tested parameters.

Conclusions: Expression of HER2 protein by using an univariate statistical method according to Pearson has shown a negligible negative correlation without statistical significance according to histological type by Lauren.


Correlation, Gastric cancer, HER2, Hystological type, Lauren

Full Text:



Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1-9.

Troskot B, Gamulin M. Gastric Adenocarcinoma. Medicus. 2006;15:73-87.

Gullick WJ. Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer. Breast Cancer Res. 2001;3:390-4.

Guan ZY, Ying C, Jie JW. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic signifcance. J Cancer Res Clin Oncol. 2009;135:1331-9.

Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26-33.

Hofmann M, Stoss O, Shi D, Buttner R, Kim W, Ochiai A, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.

Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995;76:720-6.

Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, et al. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis. Cancer. 1997;80:179-87.

Dohchin A, Suzuki J, Seki H, Masutani M, Shiroto H, Kawakami Y. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer. 2000;89:482-7.

Sgambato A, Migaldi M, Leocata P, Ventura L, Criscuolo M, DiGiacomo C, et al. Loss of p27 KIP1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer. 2000;89:2247-57.

Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, et al. A fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer. 2000;88:24-34.

Chung YS, Yamashita Y, Kato Y, Nakata B, Sawada T, Sowa M. Prognostic significance of T antigen expression in patients with gastric carcinoma. Cancer. 1996;77:1768-73.

Song HJ, Noh JH, Joo M, Jang KT, Park CK, Kim KM. The type of host inflammatory immune response predicts survival in EBV-associated gastric carcinomas: a multivariate analysis of 109 cases. Lab Invest 2009;89(Suppl 1):148A.

VanBeek J, Snel SN, Berkhof J, Kranenbarg EK, Middeldorp JM, Meijer CJ, et al. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol. 2006;30:59-65.

Akiyama T, Sudo C, Ogawara H. The product of the human c-erbB–2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. 1986;232:1644-6.

Gullick WJ. Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer. Breast Cancer Res. 2001;3:390-4.

Coussens L, Yang-Feng TL, Liao YC. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. 1985;230:1132-9.

Hetzel DJ, Wilson TO, Keeney GL. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992;47:179-85.

Hirashima N, Takahashi W, Yoshii S. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol. 2001;14:556-662.

Douglass Jr HO, Nava HR. Gastric adenocarcinoma. Management of the primary disease. Semin Oncol. 1985;12:32-45.

Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology. 2008;19(9):1523-9.

Tanner M. Amplification of HER2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-8.

Pinto-de-sousa J, David L, Seixas M. Clinicopathologic profiles and prognosis of gastric carcinoma from the cardia, fundus/body and antrum. Dig Surg. 2001;18:102-10.

Rech J, Arnold D, Folprecht G, Hejna M, Hofmann M, Gramatzki M. A pilot study of trastuzumab (Herceptin) monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER2-positive gastric cancer. Ann Oncol. 2006;17:Abstract 1096P.

Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306-14.

Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, Takahari D, et al. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer. 2012.

Ross JS, McKenna BJ. The HER2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.

Maehara Y, Kakeji Y, Koga T. Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery. 2002;131:85–91.

Siewert JR, Bottcher K, Stein HJ. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-61.